ARPI

Based in South Korea, ARPI is a medical AI company specializing in innovative solutions for cardiovascular health, enhancing the accuracy and efficiency of cardiac screenings through technology-driven platforms. ARPI, founded in 2021 and based in Seongnam, South Korea, focuses on developing advanced medical AI solutions for cardiovascular diagnostics. The company has secured investment from Kakao Ventures and has completed a single funding round to date. The founder's specific history is not detailed in available resources.

ARPI specializes in advanced medical AI solutions focused on cardiovascular health. Their core offerings include the 'ECG Buddy' and 'ECG Buddy Clinic,' both designed to enhance the accuracy and efficiency of cardiac screenings. The 'ECG Buddy' provides comprehensive analysis by classifying 11 types of arrhythmias and generating 10 digital biomarker risk scores for conditions such as STEMI and hyperkalemia, all accessible on a single screen. Meanwhile, the 'ECG Buddy Clinic' expands this functionality by screening for asymptomatic left ventricular dysfunction (LV dysfunction) and paroxysmal atrial fibrillation (PAF), delivering five cardiovascular biomarker risk scores tailored for both clinic and outpatient care.

The company serves a diverse client base, which includes over 90 hospitals across South Korea and potentially other regions, leveraging its products to improve patient outcomes in various healthcare settings. The revenue model for ARPI involves direct business-to-business transactions primarily with healthcare institutions, leveraging their flagship products for routine cardiac assessments. The 'ECG Buddy' and 'ECG Buddy Clinic' are positioned as medical devices certified by relevant regulatory bodies, indicating a structured sales framework that may include partnerships with hospitals and outpatient facilities. Clients engage in subscription-based arrangements for access to these solutions or may purchase on a per-use basis depending on the healthcare facility's needs.

Given the critical nature of their offerings, pricing structures are aligned with institutional budgets for medical technology, ensuring broad adoption and integration within existing healthcare practices. ARPI plans to utilize recent funding from Kakao Ventures to support the development of new products aimed at enhancing their cardiovascular diagnostic offerings. The company is also looking to expand into international markets beyond South Korea within the next two years. Specific target regions for expansion have not been disclosed, but the focus remains on increasing their footprint in the global healthcare technology sector.